Short Interest in
Teva Pharmaceutical Industries Limited (NYSE:TEVA) has seen a 36.1% increase.
Goldman Sachs has initiated a buy rating on Teva's stocks, causing their value to surge by 6%. Despite a 14% dip, the CEO claims they are 'victims of their own success.' Billionaire investor David Einhorn has included Teva among his top healthcare stock picks.
Matthew Shields sold 6,206 shares of Teva stock. Traders have been purchasing high volumes of Teva call options. Teva has outmaneuvered its sales miss. Dark horse investment firm Centaurus Financial Inc. bought a significant number of shares, showing faith in Teva's future. Teva stock has been downgraded 4%, sparking speculation on whether investors should sell.
Siemens Fonds Invest GmbH is among financial institutions who have made large Teva investments. Teva was upgraded to 'Strong-Buy' at Truist Financial.
Goldman Sachs remain bullish on branded drug upside at Teva. The company had a senior notes offering to finance debt tender offers and raised its pool tender offer.
Teva Pharmaceutical Stocks News Analytics from Wed, 23 Oct 2024 07:00:00 GMT to Sat, 07 Jun 2025 09:33:43 GMT -
Rating 5
- Innovation -4
- Information 6
- Rumor 2
